Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis

Inclusion Criteria: * Willing and able to give written informed consent for participation in the study. * Male or female, aged 18 years or above. * Subject is able (in the investigator's opinion) and willing to comply with all study requirements. * Diagnosed with MS. * Received Sativex for the relief of spasticity for at least 12 weeks prior to screening and willing to stop dosing with their own supply for the duration of the study. * Judged to have been receiving benefit from and shown tolerability to Sativex, in the investigators' and subjects' opinion. * Takes a minimum dose of Sativex of two sprays per day. * If receiving disease-modifying medications, these must have been at a stable dose for at least three months prior to screening, and willing to maintain this for the duration of the study. * Has had a stable regimen for at least 30 days prior to study entry, for all medications and non-pharmacological therapies that may have an affect on spasticity; and willing to maintain this for the duration of the study (N.B. This should be three months prior to study entry, in the case of Interferon therapy). * Willing to allow his or her general practitioner and consultant, if appropriate, to be notified of participation in the study. * Willing for his or her name to be notified to the responsible authorities for participation in this study Exclusion Criteria: * Has any concomitant disease or disorder that has symptoms of spasticity or that may influence the subject's level o…